Sclerosteosis Cell Models for Research

Sclerosteosis is an extremely rare autosomal recessive disorder characterized by progressive skeletal overgrowth, primarily due to loss-of-function mutations in the SOST gene. The global incidence is estimated at fewer than 1 per 1,000,000 live births, with the highest prevalence in the Afrikaner population of South Africa, where the carrier frequency is approximately 1 in 140 (WHO, 2023). Clinical impact includes hyperostosis of the skull, mandible, and long bones, leading to facial distortion, cranial nerve entrapment (especially hearing loss and facial palsy), and increased intracranial pressure. Mortality is often secondary to complications such as brainstem compression or increased intracranial pressure, with a median age of death in the fourth to fifth decade. There is no cure; management is symptomatic and surgical. The 5-year survival rate is not well-defined due to rarity, but early diagnosis and multidisciplinary care improve outcomes (NCI, 2023).

Sclerosteosis serves as a paradigm for understanding bone homeostasis and the Wnt/β-catenin signaling pathway. The disease is caused by mutations in SOST, which encodes sclerostin, a secreted glycoprotein that inhibits osteoblast activity by antagonizing LRP5/6. Studying sclerosteosis provides insights into bone remodeling, mechanotransduction, and potential therapeutic targets for osteoporosis and other skeletal disorders. Public datasets such as ClinVar and NCBI Gene offer variant information, while DepMap provides expression and dependency data for SOST and related genes. Open questions include the role of sclerostin in other tissues, the mechanisms of phenotypic variability, and the development of targeted therapies.

Sclerosteosis is not a malignant disease, but the molecular pathways involved overlap with those dysregulated in cancer, particularly bone metastases. Key pathways include:

• • Wnt/β-catenin signaling:

1. Sclerostin (encoded by SOST) binds to LRP5/6 and inhibits Wnt signaling.

2. Loss of sclerostin leads to constitutive Wnt activation, increasing osteoblast proliferation and bone formation.

3. In cancer, aberrant Wnt activation promotes tumor growth and bone metastasis.

• • BMP signaling:

1. Sclerostin also modulates BMP signaling, affecting osteoblast differentiation.

2. Dysregulation can contribute to osteosarcoma and other bone tumors.

• • RANKL/OPG axis:

1. Sclerostin influences the RANKL/OPG ratio, affecting osteoclastogenesis.

2. Imbalance is linked to bone destruction in metastatic disease.

• • Mechanotransduction pathways:

1. Sclerostin is downregulated by mechanical loading via PGE2 and Wnt.

2. Defects in mechanosensing contribute to skeletal pathologies.

Sclerosteosis is primarily caused by mutations in SOST. The table below summarizes key genetic alterations from ClinVar and COSMIC.

Note: Sclerosteosis is not associated with high-frequency somatic mutations as in cancer; the data reflect germline variants. COSMIC lists no somatic mutations for SOST in cancer, but SOST is downregulated in some cancers via epigenetic mechanisms.

The core deregulated network in sclerosteosis is the Wnt/β-catenin pathway. Key nodes include:

• • Sclerostin (SOST): secreted antagonist of LRP5/6.
• • LRP5/6: co-receptors for Wnt ligands.
• • β-catenin: central transcriptional co-activator.
• • GSK3β: negative regulator of β-catenin.
• • APC and Axin: components of the destruction complex.
• • RANKL and OPG: regulators of osteoclastogenesis.
• • BMPs and their receptors: interact with sclerostin.

In sclerosteosis, loss of sclerostin leads to enhanced Wnt/β-catenin signaling, promoting osteoblast differentiation and bone formation. This network is also implicated in bone metastasis, where tumor cells often hijack Wnt signaling to colonize bone.

Several cell lines are used to study sclerosteosis and related bone biology. Key lines include:

Organoids: Patient-derived bone organoids are emerging as powerful models to study sclerosteosis, as they recapitulate the 3D bone microenvironment and allow for personalized drug testing. However, their use is limited by rarity of patient samples.

Animal models are crucial for understanding sclerosteosis. Examples include:

• • Sost knockout mice: Recapitulate the high bone mass phenotype and are widely used.
• • Sost transgenic mice: Overexpress sclerostin, leading to osteopenia.
• • LRP5 gain-of-function mice: Model high bone mass syndromes.
• • Zebrafish models: Allow rapid genetic manipulation and bone visualization.
• • Induced pluripotent stem cell (iPSC)-derived osteoblasts from patients: Provide a humanized model.

These models are used for target validation and preclinical drug testing.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise SOST knockouts or knock-ins. For example:

• • SOST knockout in U2OS or SaOS-2 cells: Abrogates sclerostin expression, leading to increased Wnt signaling and osteoblast differentiation.
• • LRP5 gain-of-function knock-in: Introduces specific mutations (e.g., LRP5 T253I) to model high bone mass.
• • Reporter lines: SOST promoter-driven luciferase or GFP reporters allow high-throughput screening of modulators.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are essential for functional genomics, drug discovery, and target validation, and can be customized for specific mutations.

Knockout and knock-in cell lines are used to validate gene function. For sclerosteosis, SOST knockout lines confirm its role as a negative regulator of bone formation. Genome-wide CRISPR screens in these lines can identify synthetic lethal partners or modifiers of the phenotype. For example, knocking out SOST in osteosarcoma cells followed by CRISPR screening can reveal genes that mediate sensitivity to Wnt inhibitors.

Isogenic pairs (SOST wild-type vs. knockout) are ideal for drug screening. Compounds that mimic sclerostin or inhibit Wnt signaling can be tested for their ability to reverse the high bone mass phenotype. Resistance studies can model how cancer cells adapt to Wnt-targeted therapies, using SOST knockout lines to identify resistance mechanisms.

CRISPR synthetic lethality screens in SOST-mutant backgrounds can uncover biomarkers for diagnosis or prognosis. For instance, screening for genes that are essential only in SOST-knockout cells may reveal vulnerabilities that can be targeted therapeutically. Such screens also help identify predictive biomarkers for response to Wnt pathway inhibitors.